ZERO To Host Clinical Trials Education Webinar

WASHINGTON, Sept. 13, 2012 /PRNewswire-USNewswire/ -- ZERO – The End of Prostate Cancer and Us TOO International in partnership with OncoGenex will host a "Clinical Trials Education" webinar featuring Dr. Tomasz Beer, Deputy Director at the Oregon Health & Science University Knight Cancer Institute in Portland, OR on Sept. 19, from 6:00-7:30 p.m. EDT.

Are you considering a clinical trial? How safe are clinical trials? How do you know if your clinical trial is working? Dr. Beer will cover everything you need to know about clinical trials. If you have access to a computer with Internet access, you can take part in this interactive webinar. Register at and you will receive an email from GoTo Meeting with directions on how to join the webinar.

Wednesday, Sept. 19, 6:00 – 7:30 p.m. EDT (3:00 – 4:30 p.m. PDT)


I. What is a Clinical Trial? 

II. How Does a Clinical Trial Work? 

III. Are Clinical Trials Safe? 

IV. Who's Eligible 

V. Current Clinical Trials 

VI. Question & Answer

About ZERO — The End of Prostate Cancer (
As ZERO — The End of Prostate Cancer, we commit ourselves not only to reduce prostate cancer or alleviate the pain from the disease but to end it. We see a future where all men who have been diagnosed with prostate cancer will be cured or manage their illness with good quality of life, with the support they need to minimize physical and emotional suffering and to cope effectively throughout their cancer journeys.

To accomplish our goal, we increase research funds from the federal government to find new treatments and we fund local grants to end prostate cancer through our national event series, the Great Prostate Cancer Challenge. We conduct free testing through the Drive Against Prostate Cancer mobile testing program and educate patients, families and those at risk.



SOURCE ZERO - The End of Prostate Cancer

Suggested Articles

Merck is scouting replacements for CEO Ken Frazier with a preference toward an internal candidate, Bloomberg reports.

Bluebird Bio says the launch of Zynteglo, its first gene therapy, will not occur until 2020 while it tightens up its manufacturing processes.

Riival generics makers are squashing long-running lawsuits over their own versions of Sanofi's big-selling blood thinner Lovenox.